EcoDrugPlus

Glutamate Receptor 2-Like

Ensembl ID : ENSATEG00000002567
Gene Symbol: LOC113162551
2 Cross references
244 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2b

Ensembl ID : ENSATEG00000009755
Gene Symbol: LOC113152389
3 Cross references
254 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2c-Like

Ensembl ID : ENSATEG00000004580
Gene Symbol: LOC113156456
2 Cross references
247 Possible Orthologues:

Glutamate Receptor Ionotropic, Kainate 2-Like

Ensembl ID : ENSATEG00000014169
Gene Symbol: LOC113149853
2 Cross references
254 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1a

Ensembl ID : ENSATEG00000000871
Gene Symbol: GRIA1A
1 Cross references
252 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2b

Ensembl ID : ENSATEG00000004338
Gene Symbol: GRIA2B
3 Cross references
255 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 1a

Ensembl ID : ENSATEG00000003151
Gene Symbol: GRIN1A
3 Cross references
203 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2a, B

Ensembl ID : ENSATEG00000007389
Gene Symbol: GRIN2AB
2 Cross references
225 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2b, Genome Duplicate B

Ensembl ID : ENSATEG00000029877
Gene Symbol: GRIN2BB
3 Cross references
256 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2ca

Ensembl ID : ENSATEG00000019909
Gene Symbol: GRIN2CA
2 Cross references
249 Possible Orthologues:

Glutamate Receptor, Ionotropic, Kainate 2

Ensembl ID : ENSATEG00000024953
Gene Symbol: GRIK2
2 Cross references
252 Possible Orthologues:

Glutamate Receptor, Metabotropic 2a

Ensembl ID : ENSATEG00000004940
Gene Symbol: GRM2A
2 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).